Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Depreciation and Depletion (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Depreciation and Depletion for 6 consecutive years, with $17000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Depreciation and Depletion fell 83.81% year-over-year to $17000.0, compared with a TTM value of $256000.0 through Sep 2025, down 34.69%, and an annual FY2024 reading of $400000.0, changed 0.0% over the prior year.
  • Depreciation and Depletion was $17000.0 for Q3 2025 at Ovid Therapeutics, down from $61000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $131632.0 in Q4 2022 and bottomed at $16000.0 in Q3 2021.
  • Average Depreciation and Depletion over 5 years is $71626.5, with a median of $87000.0 recorded in 2025.
  • The sharpest move saw Depreciation and Depletion soared 537.94% in 2022, then tumbled 83.81% in 2025.
  • Year by year, Depreciation and Depletion stood at $23897.0 in 2021, then surged by 450.83% to $131632.0 in 2022, then plummeted by 36.95% to $83000.0 in 2023, then grew by 9.64% to $91000.0 in 2024, then plummeted by 81.32% to $17000.0 in 2025.
  • Business Quant data shows Depreciation and Depletion for OVID at $17000.0 in Q3 2025, $61000.0 in Q2 2025, and $87000.0 in Q1 2025.